Biotech/Health Care

U.S. drug stocks are considered a “safe haven” because their sales are less correlated with the economic environment than most sectors.

Some top firms are establishing positions to oversee their overall strategy, including new business opportunities and cost-cutting initiatives. As new drugs become harder to come by and generics encroach, the strategy person is charged with setting priorities and allocating resources more efficiently. Firms are diversifying their product lines to include consumer health care items like vitamin supplements that tend to have steady, though lower, profit margins than drug sales.

The drug industry contains a varied selection of investment opportunities … U.S. drug stocks have outperformed the S&P by an average of 7 percent in the past four recessions.

oooooooo

Charles C. Duncan, PhDJMP [email protected]

We reiterate our Market Outperform rating and $12 price target on Allos Therapeutics. On May 15, Allos surprisingly held a call to discuss interim results from its pivotal Phase II PROPEL study with pralatrexate (PDX) in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The data look promising and suggest to us that timelines could accelerate. Patient enrollment was completed in April; we expect top-line data by year-end ’08 and, if positive, for Allos to file a new drug application in first-half of 2009. Allos also has six other ongoing trials looking at PDX in other cancers (hematological and solid tumors). Our $12 price target is based on 8 times 2010 product sales, discounted at 30 percent.

We look forward to updates from the previous investigator-lead trial in PTCL, as well as information on the broader PDX clinical program (interim CTCL or NHL data) at an upcoming European hematology meeting. Additionally, in second-half ’08, we anticipate the company will bolster its balance sheet either through an equity raise (we have modeled an approximate 7-million share raise in 4Q08), or out-licensing ex-US rights to PDX, or by being acquired.

oooooooo

Damien Conover, CFAMorningstar, Inc. 312-696-6052 [email protected]

Earlier in the summer, Sanofi-Aventis announced a $2.6 billion acquisition bid for generic Czech firm Zentiva. The bid represents a 15 percent premium to Zentiva’s closing price before a previous bid by financial firm PPF Group. Since PPF lacks the operational synergies expected in a Sanofi acquisition, we don’t anticipate a bidding war between the firms. While the premium appears a little low, we believe Sanofi’s current 25 percent ownership in Zentiva will probably provide a nudge to close the deal.

We like the deal, as the acquisition provides Sanofi with additional access to the fast-growing Eastern European market. Further, with the U.S. patent expiration approaching on cardiovascular drug Plavix in 2011, the increased exposure to generic pharmaceuticals should help blunt that loss.

Sanofi-Aventis’ wide lineup of branded drugs and a robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should offset patent losses on allergy drug Allegra and cancer treatment Eloxatin. Further, Sanofi dodged a bullet in mid-2007 by holding on to patent exclusivity of blockbuster Plavix, removing a major risk hanging over the company.